demonstrated that in ERBB2+ gastric cancer (GC), THRA might be one of the sensitive biomarkers for the targeted ERBB2 treatment, and its expression level was negatively correlated with Myc activation (47). The gene discussed is THRA; the disease is gastric cancer.